Author pages are created from data sourced from our academic publisher partnerships and public sources.
Share This Author
Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
This article discusses the prevention of venous thromboembolism (VTE) and is part of the Antithrombotic and Thrombolytic Therapy: American College of Chest Physicians Evidence-Based Clinical Practice…
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
This article discusses the prevention of venous thromboembolism (VTE) and is part of the Seventh American College of Chest Physicians Conference on Antithrombotic and Thrombolytic Therapy:…
A prospective study of venous thromboembolism after major trauma.
- W. Geerts, K. Code, R. Jay, E. Chen, J. Szalai
- MedicineThe New England journal of medicine
- 15 December 1994
Venous thromboembolism is a common complication in patients with major trauma, and effective, safe prophylactic regimens are needed.
Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty.
A once-daily, 10-mg oral dose of rivaroxaban was significantly more effective for extended thromboprophylaxis than a once- daily, 40-mg subcutaneous dose of enoxaparin in patients undergoing elective total hip arthroplasty.
A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome.
The low rate of recurrent thrombosis among patients in whom the target INR was 2.0 to 3.0 suggests that moderate-intensity warfarin is appropriate for patients with the antiphospholipid antibody syndrome.
A comparison of low-dose heparin with low-molecular-weight heparin as prophylaxis against venous thromboembolism after major trauma.
Low-molecular-weight heparin was more effective than low-dose Heparin in preventing venous thromboembolism after major trauma and both interventions were safe.
Deep venous thrombosis in medical-surgical critically ill patients: Prevalence, incidence, and risk factors
Despite universal thromboprophylaxis, medical-surgical critically ill patients remain at risk for lower extremity deep venousThrombosis, and further research is needed to evaluate the risks and benefits of more intense venous thromboembolism prophylaxis.
Dalteparin versus unfractionated heparin in critically ill patients.
Among critically ill patients, dalteparin was not superior to unfractionated heparin in decreasing the incidence of proximal deep-vein thrombosis and prespecified per-protocol analyses were similar to those of the main analyses.
Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism.
Conventional- intensity warfarin therapy is more effective than low-intensity warFarin therapy for the long-term prevention of recurrent venous thromboembolism and the low- intensity regimen does not reduce the risk of clinically important bleeding.
Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis.
The results of this trial establish the efficacy of intravenous heparin in the treatment of proximal venous thrombosis and suggest a relation between the effectiveness ofHeparin and the levels of anticoagulation achieved; such a relation could explain the observed failure of the subcutaneous regimen.